Summary & Overview
HCPCS J9220: Injection of Indigotindisulfonate Sodium, 1 mg
HCPCS Level II code J9220 denotes a 1 mg injection of indigotindisulfonate sodium, an injectable diagnostic/therapeutic agent used in clinical settings. Nationally, accurate coding for drug injections matters for billing clarity, claims processing, and tracking utilization of specialized agents. This code captures the unit-based administration of the compound and is relevant across outpatient and ambulatory care environments.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of clinical context for the agent, payer-specific coverage considerations where publicly available, typical sites of service, and common billing modifiers associated with injectable drugs. The publication summarizes standard billing practice for unit-based HCPCS drug codes, highlights documentation elements important for payer adjudication, and outlines where readers can expect variability in coverage policies and prior authorization requirements.
The report provides benchmarks and policy context for managing claims with HCPCS Level II code J9220, identifies common administrative challenges in coding and billing injectable agents, and points to areas for operational attention such as accurate unit reporting and site-of-service designation. Data not available in the input will be noted where relevant.
Billing Code Overview
HCPCS Level II code J9220 represents an injection of indigotindisulfonate sodium, 1 mg. This code describes a drug administration service for a diagnostic or therapeutic injectable agent delivered by syringe or IV push as indicated by clinical need.
-
Service type: Injection of a diagnostic/therapeutic agent
-
Typical site of service: Outpatient clinic, hospital outpatient department, physician office, or other ambulatory care settings where injectable diagnostic agents are administered
Clinical & Coding Specifications
Clinical Context
Injection of J9220 (indigotindisulfonate sodium, 1 mg) is used in diagnostic procedures where an intravascular dye is required to visualize structures or assess physiology. A typical patient scenario is an adult undergoing intraoperative or interventional vascular imaging to evaluate hepatic function or to localize sentinel lymph nodes during oncologic surgery. The workflow includes pre-procedure consent and allergy review (especially for dye hypersensitivity), baseline vital signs and renal/hepatic function assessment, intravenous access placement, and administration of the calculated dose of J9220 by a qualified clinician (e.g., interventional radiologist, surgical oncologist, or anesthesiologist) in an operating room, interventional radiology suite, or endoscopy/procedure room. Real-time imaging (fluoroscopy or other modality) is performed after injection to document distribution. Post-injection monitoring focuses on hemodynamics and immediate hypersensitivity reactions; documentation should include medication name and HCPCS code J9220, dose, route, time, lot number, and any modifiers as applicable. Typical site of service is an inpatient or outpatient hospital procedure room, ambulatory surgery center, or interventional radiology suite.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
JW |